IRCCS Azienda Ospedaliero-Universitaria di Bologna
This exploratory study aims to obtain a first identification of clinical and biological characteristics related to response and toxicity to bispecific antibodies.
Having this information, currently not available in the scientific literature and to be validated in further studies, therapies with BsAbs can be addressed only to patients for whom they have proven useful, improving the results of the therapy pharmacological (more responses and less toxicity) and consequently the sustainability and efficiency of the healthcare system.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age≥18 years
Patients with histologically documented non-Hodgkin B lymphoma, with relapsed/refractory disease and candidates for BsAbs therapy (glofitamab, epcoritamab, mosunetuzumab) according to clinical indication and AIFA reimbursement criteria
obtaining signed and dated informed consent before the start of any screening or study-specific procedure
You may not be if
Evidence of concomitant and uncontrolled diseases that could affect protocol compliance or interpretation of results.